Home
What is
Hepatitis
How is it
Transmitted
Long Term
Prognosis
Complications of
HCV
Liver
Biopsy
Treatment Info
(Interferon, Herbal, etc)
Lab Tests (PCR,
Genotype,etc.)
Nutrition
& Alternative Info
Patient
Information (Support Groups, Doctor Listing,
etc)
Related
Webpages
Transplant
Info
Site
Search
HCV
Webrings
My
guestbookbook
Site
Awards
FAQ &
Disclaimers
|
Patients with Genotype 2 Have Less Severe Disease
May 21, 1996
Infectious Disease Weekly via Individual Inc. :
Patients with chronic hepatitis C involving genotype 2 have a more
favorable outcome than those with genotype 1b, according to a
report from Japan. Several recent investigators have reported that
the HCV genotype is associated with the stage of type C chronic
liver disease, but controversy remains regarding whether the
prognosis differs among hepatitis C patients infected with
different genotypes. In this study, researcher Masanori Kobayashi
and colleagues compared the long-term histological outcome of
chronic hepatitis in patients infected with HCV genotype 1 with
that in patients infected with HCV genotype 2 to clarify the
difference of pathogenicity between these genotypes. The
researchers examined 140 patients with chronic hepatitis C. The HCV
genotype was determined by the enzyme-linked immunosorbent assay
(ELISA) based on genotypes 1 and 2 specific recombinant proteins;
genotype 1 was found in 100 patients (96 were 1b and four were
indeterminate) and genotype 2 in 36. The two groups showed no
significant differences for any clinical background features.
Deterioration of the grade of liver histology during the follow- up
period was seen in 68 percent of the patients with genotype 1 as
compared with 41.7 percent of those with genotype 2 (P<.001).
Similarly, the deterioration of the stage of liver histology was
more common in the former group than in the latter (63 percent and
38.9 percent, respectively). The mean serum HCV RNA titer was
significantly higher in the patients with genotype 1 than in those
with genotype 2, and multivariate analysis showed the titer was one
of the independent factors of the deterioration of the stage. The
authors concluded that this phenomenon may be related in part to
the difference in pathogenicity between the two HCV genotypes.
"Chronic hepatitis C is generally a slowly progressive disease that
rarely subsides naturally," Kobayashi et al. wrote. "The grade and
stage of liver histology deteriorated more frequently in the
patients with genotype 1 than those with genotype 2, irrespective
of the initial liver histology. The patients with genotype 1 also
developed hepatocellular carcinoma more frequently than those with
genotype 2. The authors also found that serum HCV RNA titer, which
may reflect the replication of HCV, was significantly higher in
patients with genotype 1b. This phenomenon, also reported by
Yoshioka et al. (Hepatology 1992;16:293- 299) and Matsumoto et al.
(C Dig Dis Sci 1994;39:1273-1280), may be related to the difference
of pathogenicity between the genotypes. "Our multiple-regression
analysis, which showed the initial serum HCV RNA titer as the
independent factors of the deterioration of the stage of liver
histology, confirms this hypothesis," Kobayashi et al. wrote. "But
the initial serum HCV RNA titer is not correlated with the
development of HCC, although HCV genotype is the independent factor
in our analysis. Further study is needed to clarify the mechanism
of higher HCV RNA titer in patients with genotype 1b and whether
there is a difference between genotypes 1 and 2 in the
deterioration of liver histology and the development of HCC."
The corresponding author for this study is Kendo Kiyosawa,
The Second Department of Internal Medicine, Shinshu University
School of Medicine, 3-1- 1 Asahi, Matsumoto 390, Japan. - by Salynn
Boyles, Senior Editor [05-20-96 at 13:10 EDT, Copyright 1996,
Charles Henderson, File: c0519805.3wh] Entire contents (C) 1996 by
INDIVIDUAL, Inc., 8 New England Executive Park West, Burlington, MA
01803
Home | What is HCV | Transmission |
Future |
Complications |
Biopsy |
Treatment
| Lab |
Nutrition |
Patient |
Links | Transplant |
Webrings |
guestbookbook |
Awards |
FAQ
|
|